Benzinga | Feb 3, 2021 08:37AM EST

Novo Nordisk: Q4 Earnings Insights



Shares of Novo Nordisk (NYSE:NVO) were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share rose 14.29% year over year to $0.64, which were in line with the estimate of $0.64.

Revenue of $5,142,000,000 up by 5.74% year over year, which missed the estimate of $5,350,000,000.

Looking Ahead

Novo Nordisk hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Feb 03, 2021

Time: 07:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/oeqkkcyq

Price Action

52-week high: $73.92

Company's 52-week low was at $49.24

Price action over last quarter: Up 9.13%

Company Profile

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.